In recent trading session, Editas Medicine Inc (NASDAQ:EDIT) saw 7.94 million shares changing hands at last check today with its beta currently measuring 2.00. Company’s recent per share price level of $2.49 trading at -$0.71 or -22.03% at last check today assigns it a market valuation of $205.95M. That most recent trading price of EDIT’s stock is at a discount of -365.06% from its 52-week high price of $11.58 and is indicating a premium of 55.02% from its 52-week low price of $1.12.

For Editas Medicine Inc (EDIT), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 2.62. Splitting up the data highlights that, out of 9 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 3 suggested the stock as a Hold whereas 6 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -0.33 in the current quarter.

Editas Medicine Inc (NASDAQ:EDIT) trade information

Upright in the red during last session for losing -22.03%, in the last five days EDIT remained trading in the green while hitting it’s week-highest on Wednesday, 02/19/25 when the stock touched $2.49 price level, adding 24.55% to its value on the day. Editas Medicine Inc’s shares saw a change of 96.46% in year-to-date performance and have moved 109.66% in past 5-day. Editas Medicine Inc (NASDAQ:EDIT) showed a performance of 106.20% in past 30-days.

Wall Street analysts have assigned a consensus price target of 9 to the stock, which implies a rise of 72.33% to its recent value today. Analysts have been projecting 5 as a low price target for the stock while placing it at a high target of 10. It follows that stock’s current price would drop -100.8% in reaching the projected high whereas dropping to the targeted low would mean a loss of -100.8% for stock’s current value.

Editas Medicine Inc (EDIT) estimates and forecasts

This year revenue growth is estimated to fall -47.32% from the last financial year’s standing.

13 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of 37.17M for the same. And 4 analysts are in estimates of company making revenue of 640.25k in the next quarter. Company posted 60.05M and 1.14M of sales in current and next quarters respectively a year earlier.

Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of 2.88% during past 5 years. In 2025, company’s earnings growth rate is likely to be around -33.69% while estimates for its earnings growth in next 5 years are of 15.23%.

Editas Medicine Inc (NASDAQ:EDIT)’s Major holders

VANGUARD GROUP INC is the top institutional holder at EDIT for having 8.03 million shares of worth $37.51 million. And as of 2024-06-30, it was holding 9.8032 of the company’s outstanding shares.

The second largest institutional holder is BLACKROCK INC., which was holding about 7.78 million shares on 2024-06-30. The number of shares represents firm’s hold over 9.498 of outstanding shares, having a total worth of $36.34 million.

On the other hand, Vanguard Total Stock Market Index Fund and iShares Russell 2000 ETF are the top two Mutual Funds which own company’s shares. As of Sep 30, 2024, the former fund manager was holding 2.59 shares of worth $6.33 million or 3.14% of the total outstanding shares. The later fund manager was in possession of 2.33 shares on Nov 30, 2024, making its stake of worth around $5.7 million in the company or a holder of 2.83% of company’s stock.